6 June 2022
These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
Th...is document has been updated: Version 6 June 2022.
more
These guidelines provide new and updated recommendations on the use of point-of-care testing in children under 18 months of age and point-of-care tests to monitor treatment in people living with HIV; the treatment monitoring algorithm; and timing of antiretroviral therapy (ART) among people living w...ith HIV who are being treated for tuberculosis.
New recommendations launched today outline key new actions that countries can take to improve the delivery of HIV testing, treatment and care services by providing greater options for differentiated approaches such as, supporting HIV treatment start in the community, ensuring that children are diagnosed and treated early, and that viral load treatment monitoring is more accessible, focused and triggers clinical action
more
Summary of the main report: Direct and indirect effects of COVID-19 pandemic and response in South Asia .
It uses a series of exercises based on actual observed changes in services and intervention coverage to model impacts on mortality, hospitalizations, and ICU admissions due to COVID-19. It a...lso models the impact of nationwide stay-at-home orders to curb the spread of COVID-19 on maternal and child mortality, educational attainment of children, and the region’s economy. The study focuses on South Asia’s six most populous countries: Afghanistan, Bangladesh, Nepal, India, Pakistan and Sri Lanka and makes the case for interventions and strategies to minimise these indirect consequences.
more
This report describes findings from a telephone survey with 1,316 people conducted in February 2021. The survey examined how people respond to public health and social measures (PHSMs) to prevent COVID-19. The sample is representative of households with access to a landline or cell phone, but does n...ot include people without access to phones. As phone penetration varies by country, findings should be interpreted with caution.
more
Here you can find the various e-learning courses
Estimated number of pregnant women, number with access to at least four antenatal care visits, and those delivering in hospital settings in the Americas, 2019...
Steady progress in the scaleup of VMMC as an HIV prevention intervention in 15 eastern and southern African countries before the SARS-CoV2 pandemic
Los pueblos indígenas presentan tasas más altas de morbilidad y mortalidad por tuberculosis (tb) que los demás grupos étnicos. El acceso limitado a servicios de salud debido a la ubicación geográfica y a problemas del conflicto armado los mantiene aislados. En este estudio se pr...esenta un análisis de la situación epidemiológica de la tb en pueblos indígenas, y se identifican factores socioculturales que pueden ayudar a mejorar el control de la enfermedad.
more
This document provides answers to FAQs healthcare providers and staff may have about COVID-19 vaccines
خطة النقاط الست للاستجابة والتعافي ووضع رؤية جديدة لعالم ما بعد الجائحة لكل طفل
This resource explains how WHO EUL COVID-19 vaccines without vaccine vial monitor or VVM should be handled at the vaccination site, to ensure that safe and potent vaccines are administered.
This document has been updated: 31 August 2021
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
Biweekly situation reports
People-centered approaches that help communities maintain protective behaviours and follow guidelines set out by public health and government agencies are more important than ever. The evidence is clear, communities play a role in preventing and controlling epidemics and they are best able to take a...ction and slow or stop the spread of disease when properly engaged and empowered. This toolbox in 2 parts offers best practice approaches to community engagement with families. Promoting individual and joint responsibilities for the safety of the family, this toolbox aims to bring families and households together to manage shared risks and agree to safe behaviours critical for their safety and the safety of their community.
more